DNA Vaccine Protects Against Toxic Proteins Linked to Alzheimer’s
A new DNA vaccine when delivered to the skin prompts an immune response that produces antibodies to protect against toxic proteins associated with Alzheimer’s disease – without triggering severe brain swelling that earlier antibody treatments caused in some patients. Two studies from the Peter O’Donnell Jr. Brain Institute demonstrate in animals how a vaccine containing DNA of the toxic beta-amyloid protein elicits a different immune response that may be safe for humans. The vaccine, which will likely be tested further by the U.S. Food and Drug Administration (FDA), is on a shortlist of promising antibody treatments that may eventually help settle a high-stakes debate of whether amyloid is a vital target for preventing or curing Alzheimer’s.
Click here to read more.
NeuroSafe 2019 Symposium
Aug. 8-9, 2019; Minneapolis
SNSA Congress 2019
Aug. 8-11, 2019; Cape Town, South Africa
2019 Managing Coding and Reimbursement Challenges
Aug. 22-24, 2019; Rosemont, Ill.
2019 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 28-31, 2019; Orlando, Fla.
Sept. 8-11, 2019; Leuven, Belgium